

- **Supplementary Table4. The expression level of protein biomarkers and their association with clinical factors in RE**

Molecular Marker	Ctr	RE		FCD	P value
		Epilepsy duration			
p-S6(Ser240/244)/S6	96.67±6.01	163.77±14.86	r=-0.30; p=0.47	202.47±47.47	P₁=0.02 / P ₂ =0.34
p-AKT(Ser473)	100.00±1.59	255.36±34.22	r=0.41; p=0.32	234.81±26.46	P₁=0.02 / P ₂ =0.66
p-p44/42MAPK(Erk1/2)	101.16±4.69	527.60±112.59	r=0.85^{**}; p=0.00^{**}	220.34±44.80	P₁=0.00^a/ P₂=0.03^a
p-ULK1(Ser757)	100.00±0.89	234.91±45.39	r=-0.25; p=0.52	218.29±74.41	P₁=0.48^a / P ₂ =0.78 ^a
p-Stat3(Tyr705)	51.13±4.72	248.95±63.74	r=0.58; p=0.42	271.73±103.41	P₁=0.05 / P ₂ =0.84

Statistical tests included Pearson correlation analyses (for epilepsy duration) and unpaired t tests / ^a Welch's t test (for RE VS Ctr or RE VS FCD).

Values represent group means ± S.E.M, expressed as % of control. Statistically significant are in bold type. ^{**}: significant correlation was observed at the 0.01 level. P₁: RE VS Ctr; P₂: RE VS FCD.